Parsatuzumab is a humanized monoclonal antibody that acts as an immunomodulator by binding to EGFL7; it selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting angiogenesis and reducing resistance to vascular endothelial growth factor (VEGF) inhibition.